How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

156 results for

HIV related Myelopathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. (Full text)

Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. The correlation between virus load and specific cytotoxic T-lymphocyte (CTL) frequency during the chronic phase in human immunodeficiency virus type 1 (HIV-1) infection has been found to be negative in cross-sectional studies. We report here that, in infection with the related retrovirus human T-cell leukaemia virus type 1 (HTLV-1), the correlation is positive (...) in asymptomatic carriers and zero in patients with the associated inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). We demonstrate that the direction of the correlation may depend on the efficacy of the CTL response using mathematical models. We conclude that the CTL response is effective in asymptomatic carriers of HTLV-1, but ineffective in patients with HAM/TSP. Virus-mediated impairment of specific CTL production in HIV-1 infection can account for the negative

2001 Proceedings. Biological sciences / The Royal Society PubMed

142. Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. (Full text)

Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. Human immunodeficiency virus type 1 (HIV-1) has been clearly associated with a variety of new illnesses, including profound immunodeficiency (acquired immune deficiency syndrome [AIDS]), wasting syndromes (formerly termed AIDS-related complex [ARC]) and neurologic syndromes, including neuropathy, myelopathy and encephalopathy (often termed subacute encephalitis or AIDS dementia complex). HIV-1 (...) preferentially infects T lymphocytes by binding to a membrane receptor protein, CD4, associated with helper function. The virus can also attack macrophages and, possibly, other cells such as neuronal cells, colonic epithelial cells and B lymphocytes. Infection of macrophages or monocytes may be involved in neurologic disease. Knowledge about HIV-1 has rapidly increased, and investigators have characterized its structure, ways in which it infects cells, replicates and is cytopathic for certain cells, and how

1988 CMAJ: Canadian Medical Association Journal PubMed

143. Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

) or OI-defining condition within 30 days prior to entry Any condition or history of any condition, other than that related to HIV infection or antiretroviral therapy, that would add confusion to the diagnosis of dideoxynucleoside analogue-associated DSPN Pregnancy or breast-feeding Active malignancy Seizure disorder or history of seizure within 90 days of entry Current or history of bipolar disorder Certain drugs within 30 days of study entry Addition of certain pain medication during the 60 days (...) in HIV patients who have taken certain anti-HIV drugs. Condition or disease Intervention/treatment Phase HIV Infections Peripheral Nervous System Diseases Drug: Acetyl-L-carnitine Not Applicable Detailed Description: Distal symmetric peripheral neuropathy (DSPN) is the most frequent neurologic complication of HIV infection and its treatments. NRTIs, particularly dideoxy-NRTIs, represent a significant risk factor for developing neuropathy. To date, there are no effective treatments for DSPN. Studies

2002 Clinical Trials

144. Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS

or active CNS disease, potentially from opportunistic infection or neoplasm resulting from HIV infections, that could interfere with the evaluation of neuropathy. Other CNS disease (e.g., myelopathy) that could complicate the evaluation of neuropathy. Active life-threatening illness other than AIDS. Concurrent Medication: Excluded: Dapsone. Hydralazine. Isoniazid (INH). Current use of tricyclic antidepressants, anticonvulsants, or clonidine unless the patient has used the drug without a change in dose (...) to Publications: MacFadden DK, Doob PR. Role of peptide T in palliation of HIV-1-related painful peripheral neuropathy. Int Conf AIDS. 1991 Jun 16-21;7(2):225 (abstract no WB2173) Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 115A 01 First Posted: August 31, 2001 Last Update Posted: June 24, 2005 Last Verified: March 1993 Keywords provided by NIH AIDS Clinical Trials Information Service: Peptide T HIV-1 Administration, Intranasal Acquired Immunodeficiency

1999 Clinical Trials

145. Study and Surgical Treatment of Syringomyelia

spinal subarachnoid pressure waves occur with every heartbeat and act on the spinal cord above the block to drive CSF into the spinal cord and create a syrinx. Presyringomyelia, a recently described state of spinal cord edema associated with progressive myelopathy and obstruction in CSF flow, is a precursor stage to syringomyelia that is consistent with this hypothesis. Because of the importance of this condition to the pathophysiology of syringomyelia, we will also study patients (...) for study information Study Type : Observational Actual Enrollment : 50 participants Official Title: Establishing the Pathophysiology of Primary Spinal Syringomyelia Study Start Date : February 8, 2001 Study Completion Date : May 18, 2011 Resource links provided by the National Library of Medicine related topics: resources: Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important

2001 Clinical Trials

146. Evaluation of Patients With HAM/TSP

T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. Recently, a large body of literature supports other inflammatory manifestations, some neurological such as myositis, due to HTLV-1 infection. Studies of HLTV-2 clinical manifestations have largely been confounded by concomitant HIV-1 infection or IV drug abuse making the establishment of clear relationship (...) , individualas with indeterminate HTLV sero-status, and healthy volunteers are eligible to participate in this protocol. Some individuals sero-positive for HTLV may have associated diseases including but not limited to HTLV-1 associated myelopathy/tro astic paraparesis (HAM/TSP) and HTLV associated inflammatory myositis. Design and Outcome Measures: A longitudinal assessment of clinical, virological and immunological progression inHTLV related disease will be accomplished through periodic testing

1999 Clinical Trials

147. Clinical standards & management of acquired syphilis in HIV-positive patients

: • Generalised lymphadenopathy • Splenomegaly • Hepatitis • Skin rashes and/or alopecia • Oral manifestations • Cognitive impairment • Meningitis • Cranial nerve palsies • Myelopathies • Uveitis (commoner in HIV-positives [17]) Although open to debate, there appears to be a significant risk of neurological involvement in early syphilis in patients who are HIV-positive [9,18,19] and so it appears plausible that neurological symptoms may be more likely in the context of HIV. Therefore a high index of suspicion (...) puncture MINIMUM STANDARD: All HIV-infected patients with positive syphilis serology must have a full documented neurological examination. If neurological symptoms or signs are present, a head scan and lumbar puncture is required to exclude other HIV related conditions. Asymptomatic HIV positive patients do not require a lumbar puncture unless they are going to be treated with a course of antibiotics where there is uncertainty about whether CSF treponemicidal levels will be achieved. Procaine

2002 British Association for Sexual Health and HIV

148. Epoetin Alfa for HIV-Associated Neuropathy Trial

) or OI-defining condition £30 days from Visit 1. Subject has active major disease, both HIV-related and non-HIV-related including, but not limited to, cardiac disease, pulmonary, or hepatorenal, which in the opinion of the investigator might affect the study. Subject is pregnant or breast-feeding. Subject has any currently active malignancy, or a history of any previous malignancy with the exception of skin squamous cell carcinoma or basal cell carcinoma. Subject has received any investigational (...) Epoetin Alfa for HIV-Associated Neuropathy Trial Epoetin Alfa for HIV-Associated Neuropathy Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Epoetin Alfa for HIV-Associated Neuropathy Trial The safety

2007 Clinical Trials

149. Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

unless the squamous cell carcinoma requires ongoing therapy. Neurologic disease including dementia, peripheral neuropathy, myelopathy (CDC category IVb). Concurrent Medication: Excluded: Antimetabolites. Alkylating agents. Drugs with known hepatic or bone marrow toxicity. Patients with significant organ dysfunction will be excluded. Prior Medication: Excluded: Antimetabolites. Alkylating agents. Excluded within 30 days of study entry: Any investigational medication. Drugs with anti-HIV activity (...) AIDS-Related Complex Antiviral Agents Biological Availability 1-Deoxynojirimycin Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome AIDS-Related Complex Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immune System Diseases Slow Virus Diseases Miglustat Enzyme Inhibitors Molecular Mechanisms

1999 Clinical Trials

150. Progressive neurological dysfunction during latent HIV infection. (Full text)

Progressive neurological dysfunction during latent HIV infection. OBJECTIVE--To determine whether the delayed conduction through the spinal cord and peripheral nerves seen in patients with AIDS is related to infection with HIV or to the presence of an immunodeficient state. DESIGN--Two year prospective follow up study of electrophysiological measurements in subjects positive for HIV antibody but without AIDS. SETTING--HIV screening clinic and clinical departments in a university hospital (...) %). The conduction time from the gluteal crease to T12 was increased by a mean of 32.0% (5.0%) whereas that in the median and tibial nerves by only 5.6% (1.0%) and 2.2% (2.2%) respectively. CONCLUSIONS--A mild and slowly progressive peripheral neuropathy of the axonal type and a more severe progressive myelopathy or myeloradiculopathy occur concomitantly with early HIV infection, possibly as the result of a direct neurotropic action of HIV.

1989 BMJ : British Medical Journal PubMed

151. A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection

: April 3, 2012 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Collaborator: Boehringer Ingelheim Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID) Study Details Study Description Go to Brief Summary: To assess the efficacy, safety, and tolerability of amitriptyline hydrochloride versus mexiletine hydrochloride in reducing pain intensity in patients with HIV-related painful peripheral neuropathy. No large-scale controlled (...) clinical trials of symptomatic therapy for painful HIV-related neuropathy have been attempted. Both amitriptyline and mexiletine have been useful in the management of painful neuropathies; however, both are associated with certain toxicities. In this comparative study of amitriptyline and mexiletine, benztropine mesylate also will be included as an active placebo to mimic the side effects of the study drugs. Condition or disease Intervention/treatment Phase HIV Infections Peripheral Nervous System

1999 Clinical Trials

152. A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

Study Type : Interventional (Clinical Trial) Enrollment : 270 participants Masking: Double Primary Purpose: Treatment Official Title: A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy Actual Study Completion Date : February 1999 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National (...) A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

1999 Clinical Trials

153. Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00272480 Recruitment Status : Completed First Posted : January 6, 2006 Last Update Posted : May 28, 2015 Sponsor: Imperial College London Information provided by: Imperial College

2006 Clinical Trials

154. Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00076843 Recruitment Status : Completed First Posted : February 4, 2004 Last Update Posted : April 4, 2019 Sponsor: National Institute of Neurological Disorders

2006 Clinical Trials

155. Treatment of AIDS Vacuolar Myelopathy With Methionine

by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present (...) in low doses in the normal diet, can improve myelopathy or stop its progression. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 56 participants Allocation: Randomized Masking: Double Primary Purpose: Treatment Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing

2002 Clinical Trials

156. Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Study Start Date : September 1998 Study Completion Date : September 2004 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>